| 1 |
Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update[J]. Discov Med, 2019, 27(148): 167-170.
|
| 2 |
王洪武，金发光. 晚期非小细胞肺癌多域整合治疗策略[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(4): 457-461.
|
| 3 |
游雅婷，毕周奎，郭 亮，等. EGFR罕见突变非小细胞肺癌临床病理特征及疗效分析[J/CD]. 中华肺部疾病杂志(电子版), 2023, 16(5): 635-639.
|
| 4 |
Le X, Nilsson M, Goldman J, et al. Dual EGFR-VEGF pathway inhibition: A promising strategy for patients with EGFR-Mutant NSCLC[J]. J Thorac Oncol, 2021, 16(2): 205-215.
|
| 5 |
Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives[J]. Crit Rev Oncol Hematol, 2021, 157: 103194.
|
| 6 |
尉腊革，李 毅，张建辉，等. 单孔胸腔镜肺癌根治术后不同胸腔引流液量时拔管的康复分析[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 478-480.
|
| 7 |
Mithoowani H, Febbraro M. Non-small-cell lung cancer in 2022: A review for general practitioners in oncology[J]. Curr Oncol, 2022, 29(3): 1828-1839.
|
| 8 |
Chen Z, Fillmore CM, Hammerman PS, et al. Non-small-cell lung cancers: a heterogeneous set of diseases[J]. Nat Rev Cancer, 2014, 14(8): 535-546.
|
| 9 |
Relli V, Trerotola M, Guerra E, et al. Abandoning the notion of non-small cell lung cancer[J]. Trends Mol Med, 2019, 25(7): 585-594.
|
| 10 |
Nambirajan A, Singh V, Bhardwaj N, et al. SMARCA4/BRG1-deficient non-small cell lung carcinomas: A case series and review of the literature[J]. Arch Pathol Lab Med, 2021, 145(1): 90-98.
|
| 11 |
高永山，张志杰，付 伟，等. 单操作孔胸腔镜肺段切除治疗早期非小细胞肺癌的学习曲线[J]. 中国微创外科杂志，2021, 21(12): 1072-1076.
|
| 12 |
Husson O, de Rooij BH, Kieffer J, et al. The EORTC QLQ-C30 summary score as prognostic factor for survival of patients with cancer in the " Real-World" ：Results from the population-based PROFILES registry[J]. Oncologist, 2020, 25(4): e722-e732.
|
| 13 |
Wu M, Miska J, Xiao T, et al. Race influences survival in glioblastoma patients with KPS≥80 and associates with genetic markers of retinoic acid metabolism[J]. J Neurooncol, 2019, 142(2): 375-384.
|
| 14 |
Liang G, Meng W, Huang X, et al. miR-196b-5p-mediated downregulation of TSPAN12 and GATA6 promotes tumor progression in non-small cell lung cancer[J]. Proc Natl Acad Sci U S A, 2020, 117(8): 4347-4357.
|
| 15 |
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.
|
| 16 |
Russo A, Franchina T, Ricciardi GRR, et al. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going[J]. Crit Rev Oncol Hematol, 2017, 117: 38-47.
|
| 17 |
Selvaggi G, Scagliotti GV. Histologic subtype in NSCLC: does it matter？[J]. Oncology (Williston Park), 2009, 23(13): 1133-1140.
|
| 18 |
Landre T, Justeau G, Assié JB, et al. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: A Meta-analysis of randomized-controlled trials[J]. Cancer Immunol Immunother, 2022, 1(3): 719-726.
|
| 19 |
De Ruysscher D, Dingemans AM, Vooijs M, et al. PD-(L)1 inhibition and cardiac damage: A relevant toxicity？[J]. J Thorac Oncol, 2018, 13(4): 478-479.
|
| 20 |
Myers CJ, Lu B. Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues[J]. Int J Radiat Oncol Biol Phys, 2017, 99(5): 1129-1136.
|
| 21 |
Kim S, Kim MY, Koh J, et al. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas[J]. Eur J Cancer, 2015, 51(17): 2698-2707.
|
| 22 |
Xu P, Zhang P, Sun Z, et al. Surgical trauma induces postoperative T-cell dysfunction in lung cancer patients through the programmed death-1 pathway[J]. Cancer Immunol Immunother, 2015, 64(11): 1383-1392.
|
| 23 |
Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: Beyond discovery and development[J]. Cell, 2019, 176(6): 1248-1264.
|
| 24 |
Zhao Y, Adjei AA.Targeting angiogenesis in cancer therapy: Moving beyond vascular endothelial growth factor[J]. Oncologist, 2015, 20(6): 660-673.
|
| 25 |
Zhang C, Wang N, Tan HY, et al. Targeting VEGF/VEGFRs pathway in the antiangiogenic treatment of human cancers by traditional Chinese Medicine[J]. Integr Cancer Ther, 2018, 17(3): 582-601.
|